Invex Therapeutics Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 3
1 (33.3%)A Trial to Determine the Efficacy and Safety of Presendin in IIH
Phase 3
Terminated
- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Drug: PlaceboDrug: Presendin
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Invex Therapeutics Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05347147
- Locations
- 🇺🇸
UCHealth Sue Anschutz-Rodgers Eye Center - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸University of Miami Leonard M. Miller School of Medicine (UMMSM) - Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸University of Minnesota Health, Minneapolis, Minnesota, United States
News
No news found